Accepted abstracts and posters provide key updates on Xeomin (incobotulinumtoxinA) and Radiesse.

Merz Aesthetics will present data from its medical aesthetics portfolio, including Xeomin (incobotulinumtoxinA) and Radiesse at the American Society of Dermatologic Surgery (ASDS) 2020 annual meeting to be held online Friday, October 9 to Sunday, October 11.

“We’re excited to virtually participate at the ASDS meeting and share several data presentations from our leading treatment portfolio, which include findings on Xeomin’s safety and prolonged duration of effect in a dose-ranging study,” said Terri Phillips, MD, chief medical affairs officer, Merz Aesthetics.

The following presentations will also be shared virtually at the ASDS meeting. Products mentioned below have not been studied in combination use by Merz Aesthetics.


  • IncobotulinumtoxinA demonstrates safety and prolonged duration of effect in a dose-ranging study for glabellar lines; Michael H. Gold, MD
    Sunday, October 11, 10:45 am to 10:48 am (ET)

This manuscript was also recently published in the October issue of the peer-reviewed Journal of Drugs and Dermatology (JDD)


  • Is it possible to interfere in the eyebrow shape and positioning while injecting Incobotulinumtoxin A into the brow depressors and also the frontalis?; Carla Pecora, MD
    Saturday, October 10, 11:09 am to 11:12 am
  • Adaptation of Face Attractiveness; Kate Goldie, MD
    Sunday, October 11, 10:36 am to 10:39 am

Scientific ePosters will be viewable by attendees for the duration of the meeting beginning on Friday, October 9 until Sunday, October 11. Presentations include:

  • Calcium hydroxylapatite microspheres provide organization into unorganized collagen networks leading to improvement of skin attractiveness; Gabriela R. Casabona, MD
  • B.UP technique: safety assessment, effectiveness and satisfaction: Report 10 cases; Rossana Vasconcelos, MD
  • Changing the architecture of the midface; Kate Goldie, MD